The ASTCT Pharmacy SIG May 2022 Journal Club aired on May 11, 2022. This webinar consists of two, 30-minute journal club presentations, which include 20 min for presentation and 10 min for discussion/Q and A.

Presenters & Articles

Arthur Nguyen, PharmD 

PGY2 Oncology Resident, Oregon Health and Science University

Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma

Elizabeth A. Meszaros, PharmD 

PGY2 Hematology/Oncology Pharmacy Resident, South Texas Veterans Healthcare System

Posttransplant Cyclophosphamide for Prevention of Graft-versus-Host Disease: The Prospective Randomized HOVON-96 Trial

Session Learning Objectives:

Upon completion of the activity, participants should be able to:

1. Evaluate the safety and efficacy of Axicabtagene Ciloleucel for the treatment of large B-cell lymphomas (LBCL).
2. Review current standards of care for Graft-versus-Host Disease (GVHD) prevention for Matched Related Donors (MRD) and Matched Unrelated Donor (MUD) peripheral blood allogeneic hematopoietic stem cell transplants (alloHSCT).
3. Evaluate the utility of post-transplant cyclophosphamide (PTCy) combined with a short course of cyclosporine (CsA) as compared to mycophenolic acid (MPA) with CsA for GVHD prophylaxis in patients receiving MRD and MUD peripheral blood alloHSCT.

The France Foundation is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education and will award 1.0 CEU to pharmacists who complete the activity, complete the registration and evaluation forms, and successfully pass a posttest (>75%). There is no fee to participate in this activity. This is a knowledge-based educational activity. Your CE credits will be submitted electronically to the CPE Monitor. CE providers must upload participant information within 60 days from the date the participant completed the activity. Please submit all evaluations and credit requests no later than 30 days after you complete this activity to ensure your credit fulfillment, as CE credit cannot be awarded past 60 days from the activity date. 

Full CE information, including presenter disclosures and accreditation information, can be found in the Handouts tab or directly downloaded by clicking here.

ASTCT April Journal Club Session

This journal club aired live on April 20, 2022, as a part of the expanded ASTCT Journal Club. This webinar consisted of two, 30-minute journal club presentations, which included 20 min for presentation and 10 min for discussion/Q and A.

Presenters & Articles

Dr. Patrick Moore, Loyola University Medical Center

Biologic and Clinical Efficacy of LentiGlobin for Sickle Cell Disease

Dr. Paramveer Singh, Karmanos Cancer Institute

Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome

On Wednesday, March 23 at 1 PM CST, ASTCT presented the second webinar in its AML webinar series sponsored by Vor Biopharma. 

Speakers and Moderator:

Moderator: Antonio Vaz de Macedo, MD; Hospital da Policia Militar

Presenter: Reshma Ramlal, MD, FACP; University of Kentucky Markey Cancer Center

Panelists:

Marcos de Lima, MD; Ohio State University

Mark Levis, MD, PhD; Johns Hopkins

The 'Recommended Timing for Transplant Consultation' guidelines were updated and published jointly by the National Marrow Donor Program®/Be The Match® (NMDP) and the American Society for Transplantation and Cellular Therapy (ASTCT) in 2022. 

This article titled 'American Society for Transplantation and Cellular Therapy Guidelines for Fellowship Training in Hematopoietic Cell Transplantation and Immune Effector Cell Therapy' was published in the March 2022 issue of Transplantation and Cellular Therapy Journal. It is an updated edition of a similar article published back in 2012, but updated to account for best practices. 

Join Dr. Kirk R. Schultz from the University of British Columbia as he discusses new and emerging therapies in cGvHD.  In this 20 min. presentation, he focuses on the future directions of treatment for cGvHD, including the idea of synergistic therapy and how biomarkers may be used to personalize therapy. 

Activity Title: Emerging Treatments in Chronic GvHD

Topic: cGVHD

Accreditation Type: AMA PRA Category 1 Credit(s)™ 

Release Date: 2/25/2022

Expiration Date: 2/24/2023

Estimated Time to Complete Activity: 20 mins

LEARNING OBJECTIVES
Upon completion of the activity, participants should be able to:

• Assess emerging therapies for cGvHD from the standpoint of mechanism of action (MOA), clinical efficacy, and safety

FACULTY 
Steven Pavletic, MD, MS
Head, Graft-Versus-Host Disease and Late Effects Section
Center for Cancer Research
National Institute of Health
Bethesda, MD

Kirk Schultz, MD
Investigator, Michael Cuccione Childhood Cancer Research Program
Director, Michael Cuccione Childhood Cancer Research Program
British Columbia Children’s Hospital
Professor, Division of Hematology and Oncology and Department of Pediatrics
University of British Columbia
Vancouver, BC

Kirsten Williams, MD
Pediatric Hematologist/Oncologist, Aflac Cancer & Blood Disorders Center
Children’s Healthcare of Atlanta
Associate Professor of Pediatrics
Emory University School of Medicine
Atlanta, GA

Olaf Penack, MD
Department of Hematology, Oncology and Tumor Immunology
Charité-Universitätsmedizin Berlin
Berlin, Germany 

METHOD OF PARTICIPATION/HOW TO RECEIVE CREDIT
Technical Requirements: http://www.francefoundation.co...
1. There are no fees for participating in and receiving credit for this activity 
2. Review the activity objectives and CME/CE information
3. Complete the CME/CE activity 
4. Complete the online posttest. A score of at least 75% is required to successfully complete this activity. The participant may take the test until successfully passed.
5. Complete the CME/CE evaluation/attestation form. This form provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
6. Credit documentation/reporting:
• If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download

ACCREDITED PROVIDER
This activity is provided by The France Foundation and produced in collaboration with the American Society for Transplantation and Cellular Therapy (ASTCT).

TARGET AUDIENCE
This activity is intended for oncologists, hematologists, physician assistants, nurse practitioners, pharmacists, and other health care professionals involved in treating and managing patients with cGVHD.

STATEMENT OF NEED
A significant number of patients—some 30% to 70%—will develop cGVHD after allo-HSCT. It typically manifests during the first year after transplantation, but it can occur several years later. cGVHD is also the leading cause of non-relapse mortality in allo-HSCT patients. The earliest possible diagnosis is critical, as once patients meet diagnostic criteria for GVHD, they may have already developed significant morbidity and possibly even irreversible organ damage. Guidelines and consensus statements from the National Institutes of Health (National Cancer Institute; NIH/NCI), the European Society for Blood and Marrow Transplantation (ESBMT), and the National Comprehensive Cancer Network (NCCN) exist to help diagnose, stage, and manage cGVHD. Unfortunately, uptake and use of guidelines have been inconsistent and variable.

ACCREDITATION STATEMENT  
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The France Foundation and American Society for Transplantation and Cellular Therapy. The France Foundation is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION
Physicians
The France Foundation designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

DISCLOSURE POLICY
In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) and American Society for Transplantation and Cellular Therapy (ASTCT) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF and ASTCT resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, TFF and ASTCT seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF and ASTCT are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Activity Staff Disclosures 
The planners, reviewers, editors, staff, CME committee, or other members at The France Foundation who control content have no relevant financial relationships to disclose.

The planners, reviewers, staff, or other members at American Society for Transplantation and Cellular Therapy who control content have no relevant financial relationships to disclose.

Faculty Disclosures - Content Creators 
The faculty listed below report that they have no relevant financial relationships to disclose:
• Kirsten Williams, MD
• Kirk Schultz, MD

The following faculty report that they have relevant financial relationships to disclose: 
• Olaf Penack, MD, has done non-CE consulting for Jazz, Gilead, MSD, Omeros, Priothera, Shionogi, and SOBI. He has served on the speaker’s bureau for Astellas, Gilead, Jazz, MSD, Neovii Biotech, Novartis, Pfizer, and Therakos. He has also done contract research for Gilead, Incyte, Jazz, Neovii Biotech, and Takeda.
• Steven Pavletic, MD, MS has done contract research for Kadmon, Eli Lilly, and Pharmacyclins.

DISCLOSURE OF UNLABELED USE
TFF and ASTCT require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF and ASTCT do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information. 

COMMERCIAL SUPPORT ACKNOWLEDGMENT
This activity is supported by an educational grant from Incyte.

DISCLAIMER 
The France Foundation and American Society for Transplantation and Cellular Therapy present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation, American Society for Transplantation and Cellular Therapy, and the commercial supporter(s) assume no liability for the information herein.

COPYRIGHT INFORMATION
Copyright © 2021 The France Foundation. Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software ("Materials") found on the Site subject to the following terms, conditions, and exceptions: 
• The materials are to be used solely for personal, noncommercial, informational, and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered. 
• Materials may not be published, uploaded, posted, or transmitted (other than as set forth herein), without The France Foundation's prior written permission 

PRIVACY POLICY
The France Foundation protects the privacy of personal and other information regarding participants and educational collaborators. The France Foundation will not release personally identifiable information to a third party without the individual's consent, except when such information is required for reporting purposes to the ACCME.

The France Foundation maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse, or alteration of information that we have collected from you.

Additional information regarding The France Foundation’s Privacy Policy can be viewed at http://www.francefoundation.com/privacy. 

CONTACT INFORMATION
If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.

On Tuesday, February 22 at 12 PM CST, ASTCT kicked off a two-part webinar series on AML sponsored by Vor Biopharma. 

Speakers and Moderator:

Moderator: Reshma Ramlal, MD, FACP; University of Kentucky Markey Cancer Center

Speaker: Muhammad Husnain, MD; University of Arizona

Panelists:

Stefan Ciurea, MD; University of California Irvine

Uday Popat, MD; The University of Texas, MD Anderson Cancer Center 

This webinar aired on January 20, 2022 at 1:30 PM CT, as the sixth and final installment of the ASTCT CAR T Webinar Series. This webinar featured presentations from Dr. Debora Barton, Dr. Michael Caligiuri, and Dr. Nirav Shah highlighting novel therapies and opportunities for the future directions of the field. The presentations were followed by a robust panel discussion led by Dr. Yan Leyfman and Dr. Armin Ghobadi.

Thank you to Janssen Oncology and Legend Biotech for their generous support of this webinar series.

This webinar series debuted in June 2021, highlighting new developments and cutting edge research in the field of CAR T. Recordings and slides from the live webinars have been posted here for your easy viewing.

Thank you to Janssen Oncology and Legend Biotech for their generous support of this webinar series.

ASTCT January Journal Club Session

This webinar aired on January 19, 2022 at 12:00 PM CT as a part of the expanded ASTCT Journal Club. This webinar consisted of two, 30-minute journal club presentations, which included 20 min for presentation and 10 min for discussion/Q and A.

Presenters & Articles

Dr. Amanda Johnson, Oregon Health & Sciences University

Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma

Dr. Sayeef Mirza, Yale University

CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial